Tarsus (TARS) CMO awarded 27,310 options and 17,161 RSUs

Rhea-AI Filing Summary

Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu reported receiving new equity awards. On March 5, 2026, she was granted stock options for 27,310 shares at an exercise price of $0.00 per share and 17,161 Restricted Stock Units.

According to the terms, 25% of the option shares vest on March 5, 2027, with the remaining option shares vesting in equal monthly installments over the following three years, subject to continuous service. The RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, also conditioned on her continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Elizabeth Yeu

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$74.9	03/05/2026		A		27,310		(1)	03/04/2036	Common Stock	27,310	$0	27,310	D
Restricted Stock Units	(2)	03/05/2026		A		17,161		(3)	(3)	Common Stock	17,161	$0	17,161	D

Explanation of Responses:

1. 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

3. The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tarsus Pharmaceuticals (TARS) report for Elizabeth Yeu?

Tarsus reported that Chief Medical Officer Elizabeth Yeu received equity awards on March 5, 2026. She was granted stock options for 27,310 shares and 17,161 RSUs, both recorded as award acquisitions rather than open-market purchases or sales.

How many stock options were granted to the Tarsus (TARS) Chief Medical Officer?

The Chief Medical Officer received 27,310 stock options with a stated exercise price of $0.00 per share. These options vest 25% on March 5, 2027, with the remaining 75% vesting monthly over the following three years, contingent on continuous service.

What are the details of the RSU grant to the Tarsus (TARS) Chief Medical Officer?

She was granted 17,161 Restricted Stock Units, each representing a right to receive one share of Tarsus common stock. The RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, subject to continued service.

When do the Tarsus (TARS) stock options granted to Elizabeth Yeu vest?

The options vest 25% on March 5, 2027, with the remaining shares vesting in equal monthly installments over three years thereafter. Vesting depends on the Chief Medical Officer maintaining continuous service with Tarsus Pharmaceuticals during the vesting period.

How do the RSU vesting terms work for the Tarsus (TARS) Form 4 filing?

The 17,161 RSUs vest in four equal parts on March 15 of 2027, 2028, 2029, and 2030. Each vested RSU entitles the holder to receive one share of Tarsus common stock, assuming continued employment through each vesting date.

Does the Tarsus (TARS) Form 4 show any insider share sales by the Chief Medical Officer?

No share sales are reported; both transactions are coded as grants or awards of equity. The filing lists one stock option award and one RSU award, each increasing the Chief Medical Officer’s direct holdings, with vesting tied to continued service at the company.